{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Back Bay Life Science Report","title":"Evolving Oncology: The Expanding Landscape of Targeted Therapies and Investment","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/6198d957\"></iframe>","width":"100%","height":180,"duration":1819,"description":"Examining the dynamic progress in targeted oncology, the episode delves into the shift from single-mutation therapies to broad pathway targeting, highlighting advances in EGFR, KRAS, and the MAPK axis. Recorded prior to the recent release of Revolution Medicine’s impressive Phase 3 data for daraxonrasib in pancreatic cancer, Mavra Nasir interviews Peter Bak for an in-depth exploration of the commercial, clinical, and investment trends influencing major pharma, biotech, and investors, showcasing why validated biology and platform innovations continue to drive both deal-making and patient impact.Key clinical challenges such as resistance, CNS coverage, and durable efficacy are unpacked, alongside the ongoing appetite for early-stage platforms and the evolution of M&A strategy in the sector.You can find our paper on the targeted oncology here: https://www.bblsa.com/analyst-reports/a-map-to-the-future-of-targeted-oncology","thumbnail_url":"https://img.transistorcdn.com/W6Lngt-BhnFN8FVt3HSPeq-NUJHgo4jaJncMb2aU6_E/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS81NjE3/MTc3NDg3NzgyNTI0/ODE3Y2ViM2Q4OWI5/MDUzMC5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}